ENHERTU Plus Pertuzumab Granted Priority Review in the U.S. as First-Line Treatment for Patients with HER2 Positive ...
AstraZeneca and Daiichi's Enhertu wins FDA priority review in breast cancer, backed by phase III data showing a 44% lower ...
AstraZeneca and Daiichi Sankyo have announced that their supplemental Biologics License Application (sBLA) for Enhertu ...
Cambridge: AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab ...
AstraZeneca ( NASDAQ: AZN) and Daiichi Sankyo have received priority review from the FDA for their supplemental marketing application for Enhertu in combination with pertuzumab, marketed by Roche ( ...
Researchers examined invasive disease-free survival rates at 4 years in a randomized phase 3 trial of adjuvant treatment for ...
Enhertu plus pertuzumab granted Priority Review in US as 1st-line treatment for patients with HER2-positive metastatic breast cancer: Cambridge, UK Thursday, September 25, 2025, 0 ...
The FDA granted priority review for trastuzumab deruxtecan in combination with pertuzumab for first-line treatment of adults ...
(Alliance News) - Daiichi Sankyo Co Ltd and AstraZeneca PLC on Wednesday said the US Food & Drug Administration has granted priority review for Enhertu in combination with pertuzumab as a first-line ...
Merck MRK and Japan’s Daiichi Sankyo announced the dosing of the first patient in the phase III HERTHENA-Breast04 study evaluating their investigational HER3-directed DXd antibody-drug conjugate (ADC) ...
The U.S. Food and Drug Administration (FDA) has granted priority review to a supplemental biologics license application for ...
The FDA has granted priority review to the supplemental biologics license application (sBLA) of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the first-line treatment of patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback